4basebio plc AIM:4BB
- Incorporated
- United Kingdom
- Chief executive
- Dr Amy Walker
- Employees
- 122
- Reports in
- GBP
- Companies House
- 13519889
Read straight from the annual reports
563p at close on 5 Oct 2026 · 7 reported years, 2019–2025
| Line | FY201912/19 | FY202012/20 | FY202112/21 | FY202212/22 | FY202312/23 | FY202412/24 | FY202512/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Gross profit | ||||||||
| Operating profit | ||||||||
| Net finance cost | ||||||||
| Profit before tax | ||||||||
| Tax charge | ||||||||
| Profit for the year | ||||||||
| EBITDA | ||||||||
| Basic EPS | ||||||||
| Diluted EPS |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
7 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Synthetic DNA product sales, nearly doubling YoY (+90%) to £1.6m
Revenue Growth: Revenues of £1.7m for the year, with synthetic DNA sales nearly doubling YoY (+90%) to £1.6m
page 4MHRA GMP manufacturing licence enabling supply of clinical-grade material
MIA IMP GMP licence received from MHRA in April 2025, authorising supply of GMP-grade synthetic DNA for clinical programmes
page 4Shift toward higher-margin, recurring GMP manufacturing revenue as clients move from research to clinical/commercial
As clients transition from early-stage research to clinical trials and full-scale commercialisation, and the requirements for High-Quality and GMP critical starting material expand, 4basebio expects a natural acceleration in high-margin, recurring revenue
page 6In-house vertical integration of enzyme manufacturing
By maintaining 100% of the Company's enzyme manufacturing requirements in-house, 4basebio is not reliant on external third parties, ensuring rapid product iteration and complete quality control
page 6£768k charge: Foreign exchange retranslation loss on 2Invest AG loan facility
page 47Revenues from all sources grew by 81% in 2025; the Group expects continued revenue growth in 2026 as new projects progress through clinical development.
page 1310 Feb 2026: Dr Amy Walker appointed CEO succeeding founder Dr Heikki Lanckriet (stepped down after 6 years, remains Non-Executive Director); David Roth stepped down as CFO and Director on the same date.
page 64The Directors are unable to recommend the payment of a dividend in respect of the year ended 31 December 2025.
page 30Auditor Crowe U.K. LLP issued an unmodified opinion but identified a material uncertainty related to going concern (the only key audit matter), owing to uncertainty over the revenue forecast and, if required, the timing/quantum of an additional fund raise. Cash and cash equivalents were £17.8m at 31 December 2025; a further €7m 2Invest AG facility drawdown was received in April 2026. Directors assessed going concern for at least 12 months from approval and continue to adopt the going concern basis.
page 33- Failure to protect intellectual property — if patents are successfully challenged or portfolio is insufficient, this could significantly impair the Group's valuation.p.12
- Commercialisation of technology is slow or delayed, restricting revenue growth or value realisation due to competitors or alternative technologies.p.12
- Access to funding to support strategic objectives — continued cash outflows until break-even, with forecast cash flows sensitive to timing/quantum of customer revenues and R&D/operating spend.p.13
- US government health policy headwinds for mRNA vaccines causing softening in the infectious disease mRNA segment and deferral of customer programmes.p.13
Read from C000003-AR-2025-ch.
6 annual reports read, FY2020 to FY2025
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (5), Company website (1)
FY2026Next report expected 26 May 2027